Patents by Inventor William J. DRURY, III

William J. DRURY, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Backbone-cyclized peptidomimetics with GLP-1R modulating activity
    Patent number: 10730911
    Abstract: Novel backbone-cyclized peptidomimetics of the general formula cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-]?? (I) wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to modulate the GLP-1 receptor. They can be used as medicaments to treat, prevent, or delay the onset of diseases, disorders or conditions in which modulation of the human GLP-1 receptor is beneficial, such as type 2 diabetes. These backbone-cyclized peptidomimetics can be manufactured by a process which is based on a mixed solid—and solution phase synthetic strategy.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: August 4, 2020
    Assignees: UNIVERSITAT ZURICH, POLYPHOR AG
    Inventors: Daniel Obrecht, Christian Bisang, Anatol Luther, Steffen Weinbrenner, John Anthony Robinson, Kerstin Moehle, Christian Steuer, William J. Drury, III
  • BACKBONE-CYCLIZED PEPTIDOMIMETICS WITH GLP-1R MODULATING ACTIVITY
    Publication number: 20180072774
    Abstract: Novel backbone-cyclized peptidomimetics of the general formula cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-]?? (I) wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to modulate the GLP-1 receptor. They can be used as medicaments to treat, prevent, or delay the onset of diseases, disorders or conditions in which modulation of the human GLP-1 receptor is beneficial, such as type 2 diabetes. These backbone-cyclized peptidomimetics can be manufactured by a process which is based on a mixed solid—and solution phase synthetic strategy.
    Type: Application
    Filed: April 6, 2016
    Publication date: March 15, 2018
    Inventors: Daniel OBRECHT, Christian BISANG, Anatol LUTHER, Steffen WEINBRENNER, John Anthony ROBINSON, Kerstin MOEHLE, Christian STEUER, William J. DRURY, III